Trial Profile
(Inhibition of NF-kB Signaling in Melanoma Therapy) A Phase I/II Clinical Trial of PS-341, a Proteasome Inhibitor, in Combination With an Extended Continuous Oral Schedule of Temozolomide in Patients With Advanced Refractory Solid Tumors With the Phase II Component Only in Patients With Melanoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Temozolomide (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Therapeutic Use
- 02 Aug 2012 Actual patient number changed from 50 to 47 as reported by ClinicalTrials.gov. (NCT00512798)
- 02 Aug 2012 Actual patient number changed from 50 to 47 as reported by ClinicalTrials.gov. (NCT00512798)
- 02 Aug 2012 Actual end date changed from 1 Feb 2010 to 1 Mar 2008 as reported by ClincialTrials.gov. (NCT00512798)